Physician profile
Constance Grace Compton
NPI 1750954046
$1,287.67
in general payments reported to CMS, 2019-2025
21 companies · $344 in 2025
The $344 reported for 2025 was more than what 78% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $570 · 2024: $374 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $229.91 | 2023-2024 | Glassia |
| Astrazeneca Pharmaceuticals LP | $151.65 | 2023-2025 | Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.42 | 2023-2024 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $105.09 | 2023-2025 | Dupixent |
| Viatris Specialty LLC | $95.85 | 2025 | Yupelri |
| Grifols USA, LLC | $76.71 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $62.56 | 2023 | Tyvaso |
| Jazz Pharmaceuticals INC. | $61.49 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $50.95 | 2024 | Opsumit, Uptravi |
| Inogen, INC. | $49.28 | 2023 | Inogen |
| Glaxosmithkline, LLC. | $44.60 | 2025 | Nucala |
| Abbvie INC. | $39.31 | 2024 | |
| Merck Sharp & Dohme LLC | $30.99 | 2023 | Zerbaxa, Recarbrio |
| Insmed, INC. | $30.25 | 2023 | Arikayce |
| Shionogi INC | $23.34 | 2023 | Fetroja |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $22.50 | 2024 | Acthar |
| Lilly USA, LLC | $20.34 | 2025 | Zepbound |
| Electromed, INC. | $19.15 | 2025 | Smartvest |
| Idorsia Pharmaceuticals US INC | $18.64 | 2023 | Quviviq |
| Baxter Healthcare | $15.76 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $13.88 | 2024 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.